Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
September 22, 2021 08:30 ET
|
Scopus BioPharma Inc.
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors Presentations to cover CpG-STAT3siRNA (DUET-01)...
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
September 21, 2021 09:00 ET
|
Scopus BioPharma Inc.
New patent covers compound and composition and methods of use forCpG-STAT3 Antisense inhibitor (CpG-STAT3ASO) New patent positions Scopus BioPharma’s Subsidiary — Duet Therapeutics — to pursue...
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board
September 14, 2021 09:00 ET
|
Scopus BioPharma Inc.
Dr. Rossi is a world leader in the development of RNA interference, the Lidow Family Research Endowed Chair and Professor and Chair of the Department of Molecular and Cellular Biology at the Beckman...
Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:00 ET
|
Scopus BioPharma Inc.
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
September 07, 2021 09:15 ET
|
Scopus BioPharma Inc.
Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope...
Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
September 03, 2021 09:25 ET
|
Scopus BioPharma Inc.
NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma Launches Duet Therapeutics
September 02, 2021 09:15 ET
|
Scopus BioPharma Inc.
Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021 Integration Creates Comprehensive, Industry-Leading Portfolio of Bi-Functional...
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company
July 12, 2021 08:30 ET
|
Scopus BioPharma Inc.
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune
June 30, 2021 09:30 ET
|
Scopus BioPharma Inc.
Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE...
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
May 31, 2021 20:30 ET
|
Scopus BioPharma Inc.
NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company’s 2021 Annual Meeting of Stockholders (“2021...